Allurion sets goal of 40,000 patients by the end of the year
Photo | Grant Welker
Allurion has expanded to a 10,000-square-foot facility at 8 Erie Drive in Natick.
Allurion Technologies, a Natick company developing a weight-loss balloon for the American market, chose World Obesity Day on Wednesday to announce an ambitious goal: treating 40,000 people by the end of the year.
Allurion didn't say how many people it has treated so far, but the company's Elipse Balloon is available today in Europe, the Middle East, and South America. The firm is working toward U.S. Food and Drug Administration approval to hit the United States market.
In three years, the company has sold 15,000 balloons, Allurion CEO and co-founder Shantanu Gaur said last September when Allurion moved into a new 10,000-square-foot office and lab on Erie Drive in Natick. Gaur said then the company could get FDA approval this year and make a market debut in late 2020.
[Related: Deflating obesity: Allurion hopes its new balloon can help patients with weight loss]
The Elipse Balloon is swallowed in a capsule in a doctor’s office visit, and is inflated through a catheter to about half the size of the stomach, large enough to help a patient lose 10% to 15% of their body weight. After four months, a polymer wears away, the balloon deflates and then passes naturally through the body, differentiating it from prior gastric balloons requiring a medical procedure.
The company has a scale to help users track their weight loss, which is connected by Bluetooth technology to an app.
Allurion announced $34 million in funding in January, after having announced $60 million in backing in September when it moved to a larger office.
WBJ Web Partners
Most Recent
Most Recent
0 Comments